Literature DB >> 9678424

Low nitric oxide production in patients with chronic renal failure.

M Blum1, T Yachnin, Y Wollman, T Chernihovsky, G Peer, I Grosskopf, E Kaplan, D Silverberg, S Cabili, A Iaina.   

Abstract

BACKGROUND: Rats with chronic renal failure have a low nitric oxide (NO) production and a diminished NO excretion. The supplementation of L-arginine has an inhibitory effect on the progression of renal insufficiency.
METHODS: The present study was designed to determine whether chronic renal failure patients have a low NO production. Plasma and urine nitrate (NO3) and nitrite (NO2), stable metabolites of NO, were measured in 83 consecutive patients with chronic renal failure. The 83 chronic renal failure patients were divided into three groups: group 1, mild renal failure (creatinine clearance >60 ml/min/1.73 m2); group 2, moderate renal failure (creatinine clearance >30 <60 ml/min/1.73 m2), and group 3, severe renal failure (creatinine clearance <30 ml/min/1.73 m2). Thirty-three healthy volunteers served as controls.
RESULTS: The daily urinary NO excretion was significantly lower in patients with moderate and severe renal failure as compared with those with mild renal failure and normal controls. The lowest values were found in the severe renal failure group. When the 24-hour urinary NO excretion or NO per milligram creatinine and the NO clearance were correlated with the renal function in all patients as a group, these parameters were directly correlated with the creatinine clearance and inversely correlated with the serum creatinine level. The plasma NO concentration was not different between the three chronic renal failure groups, but higher than in the controls. Plasma NO in renal failure patients was not correlated with the creatinine clearance or serum creatinine levels.
CONCLUSIONS: Chronic renal failure is a state of NO deficiency. Treatment strategies to increase NO production (L-arginine supplementation or other NO compounds) may prove to be useful in maintaining the renal function and slow the progression of renal disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678424     DOI: 10.1159/000045047

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  16 in total

1.  Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy.

Authors:  R Schulz; D Schmidt; A Blum; X Lopes-Ribeiro; C Lücke; K Mayer; H Olschewski; W Seeger; F Grimminger
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

Review 2.  Renal oxidative stress, oxygenation, and hypertension.

Authors:  Fredrik Palm; Lina Nordquist
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-10       Impact factor: 3.619

3.  Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Javad Habibi; Roger D Tilmon; James R Sowers; Carlos M Ferrario
Journal:  Am J Nephrol       Date:  2010-11-02       Impact factor: 3.754

4.  Effects of angiotensin type 1 receptor blockade on arginine and ADMA synthesis and metabolic pathways in fawn-hooded hypertensive rats.

Authors:  Gin-Fu Chen; Laszlo Wagner; Jennifer M Sasser; Sergey Zharikov; Natasha C Moningka; Chris Baylis
Journal:  Nephrol Dial Transplant       Date:  2010-05-19       Impact factor: 5.992

Review 5.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease.

Authors:  Chris Baylis
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

6.  Reciprocal regulation of cyclic GMP content by cyclic GMP-phosphodiesterase and guanylate cyclase in SHR with CsA-induced nephrotoxicity.

Authors:  N Hosogai; J Seki; T Goto
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

7.  Gene regulation in the vascular endothelium: why epigenetics is important for the kidney.

Authors:  Alisha Jamal; H S Jeffrey Man; Philip A Marsden
Journal:  Semin Nephrol       Date:  2012-03       Impact factor: 5.299

8.  Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis.

Authors:  R J Schmidt; S Yokota; T S Tracy; M I Sorkin; C Baylis
Journal:  Am J Physiol       Date:  1999-05

9.  Total nitric oxide production is low in patients with chronic renal disease.

Authors:  R J Schmidt; C Baylis
Journal:  Kidney Int       Date:  2000-09       Impact factor: 10.612

10.  In vivo renal arginine release is impaired throughout development of chronic kidney disease.

Authors:  Gin-Fu Chen; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.